FI945437A - Kiinteitä tebufelonidispersiokoostumuksia - Google Patents
Kiinteitä tebufelonidispersiokoostumuksia Download PDFInfo
- Publication number
- FI945437A FI945437A FI945437A FI945437A FI945437A FI 945437 A FI945437 A FI 945437A FI 945437 A FI945437 A FI 945437A FI 945437 A FI945437 A FI 945437A FI 945437 A FI945437 A FI 945437A
- Authority
- FI
- Finland
- Prior art keywords
- tebufelon
- solid
- dispersion compositions
- dispersion
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/885,932 US5281420A (en) | 1992-05-19 | 1992-05-19 | Solid dispersion compositions of tebufelone |
PCT/US1993/004050 WO1993023022A1 (en) | 1992-05-19 | 1993-04-30 | Solid dispersion compositions of tebufelone |
Publications (2)
Publication Number | Publication Date |
---|---|
FI945437A true FI945437A (fi) | 1994-11-18 |
FI945437A0 FI945437A0 (fi) | 1994-11-18 |
Family
ID=25388020
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI945437A FI945437A0 (fi) | 1992-05-19 | 1994-11-18 | Kiinteitä tebufelonidispersiokoostumuksia |
Country Status (6)
Country | Link |
---|---|
US (1) | US5281420A (fi) |
EP (1) | EP0641199A1 (fi) |
JP (1) | JPH10512845A (fi) |
CA (1) | CA2135603C (fi) |
FI (1) | FI945437A0 (fi) |
WO (1) | WO1993023022A1 (fi) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2281697A (en) * | 1993-09-14 | 1995-03-15 | Euro Celtique Sa | Laxative compositions in capsules |
GB2289624B (en) * | 1994-05-19 | 1998-03-18 | Euro Celtique Sa | Laxative compositions |
DE19545043A1 (de) * | 1995-12-02 | 1997-06-05 | Scherer Gmbh R P | Pharmazeutische Präparate zur oralen Anwendung und Verfahren zu ihrer Herstellung |
US6013280A (en) * | 1997-10-07 | 2000-01-11 | Fuisz Technologies Ltd. | Immediate release dosage forms containing microspheres |
US6350786B1 (en) * | 1998-09-22 | 2002-02-26 | Hoffmann-La Roche Inc. | Stable complexes of poorly soluble compounds in ionic polymers |
IE981008A1 (en) * | 1998-12-02 | 2000-06-14 | Fuisz Internat Ltd | Microparticles Containing Water Insoluble Active Agents |
FR2792546B1 (fr) * | 1999-04-26 | 2003-01-03 | Rhodia Chimie Sa | Composition solide comprenant au moins un tensioactif a bas point de fusion |
US6413537B1 (en) | 2000-03-10 | 2002-07-02 | Wisconsin Alumni Research Foundation | Nystatin formulation having reduced toxicity |
US20010036959A1 (en) * | 2000-04-03 | 2001-11-01 | Gabel Rolf Dieter | Carvedilol-hydrophilic solutions |
WO2001074356A1 (en) * | 2000-04-03 | 2001-10-11 | F. Hoffmann-La Roche Ag | Concentrated solutions of carvedilol |
DE10026698A1 (de) | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
BR0206825A (pt) * | 2001-02-13 | 2004-02-25 | Astrazeneca Ab | Formulação de dispersão sólida de liberação modificada, multiparticulada, processo para a preparação da formulação, uso da mesma, tablete, e, métodos para o tratamento de uma doença cardiovascular, e, para o tratamento de câncer |
IL158306A0 (en) * | 2001-05-03 | 2004-05-12 | Hoffmann La Roche | Pharmaceutical dosage form of amorphous nelfinavir mesylate |
US20030212102A1 (en) * | 2001-06-12 | 2003-11-13 | Koretke Todd W | Novel solid dispersion compositions |
AU2002330692A1 (en) * | 2001-07-02 | 2003-01-21 | Elan Corporation, Plc. | Delivery of a bioactive material |
AP1758A (en) * | 2001-09-10 | 2007-07-30 | Tibotec Pharm Ltd | Method for the preparation of hexahydro-furo [2,3-b]furan-3-ol. |
MXPA04007438A (es) * | 2002-02-01 | 2004-10-11 | Pfizer Prod Inc | Composiciones farmaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas. |
AR038681A1 (es) * | 2002-02-14 | 2005-01-26 | Solvay Pharm Bv | Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua |
WO2004069180A2 (en) | 2003-01-31 | 2004-08-19 | Smithkline Beecham Corporation | Solid dispersion compositions |
US8877241B2 (en) | 2003-03-26 | 2014-11-04 | Egalet Ltd. | Morphine controlled release system |
MXPA06001417A (es) | 2003-08-04 | 2006-05-15 | Pfizer Prod Inc | Composiciones farmaceuticas de adsorbatos de farmacos amorfos y materiales que forman microfases lipofilas. |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
DK1663217T3 (da) | 2003-08-29 | 2010-11-08 | Lifecycle Pharma As | Faste dispersioner indeholdende tacrolimus |
PL1663217T3 (pl) | 2003-08-29 | 2010-12-31 | Lifecycle Pharma As | Stałe dyspersje zawierające takrolimus |
US20080109751A1 (en) * | 2003-12-31 | 2008-05-08 | Alias Systems Corp. | Layer editor system for a pen-based computer |
US20060177403A1 (en) * | 2005-02-08 | 2006-08-10 | L'oreal | Cosmetic/dermatological compositions comprising a derivative of glucose and of vitamin F and A specific surfactant |
FR2881647B1 (fr) * | 2005-02-08 | 2007-03-30 | Oreal | Composition cosmetique ou dermatologique contenant un derive de glucose et de vitamine f et un tensioactif specifique |
KR20070025070A (ko) * | 2005-08-31 | 2007-03-08 | 주식회사 대웅제약 | 시부트라민 및 계면활성제를 함유하는 고체분산체 및 그의제조방법 |
ES2335922T3 (es) | 2005-09-23 | 2010-04-06 | F.Hoffmann-La Roche Ag | Nueva formulacion de dosificacion. |
MX2008006888A (es) | 2005-11-28 | 2008-09-30 | Marinus Pharmaceuticals | Formulas y metodos para la manufactura y uso de la ganaxolona. |
SI2530083T1 (sl) | 2006-09-22 | 2016-09-30 | Pharmacyclics Llc | Inhibitorji Bruton tirozin kinaze |
US7923026B2 (en) * | 2006-10-20 | 2011-04-12 | Solvay Pharmaceuticals B.V. | Embedded micellar nanoparticles |
AU2007312233B2 (en) * | 2006-10-20 | 2012-09-20 | Abbvie B.V. | Micellar nanoparticles of chemical substances |
ES2634153T3 (es) | 2007-05-30 | 2017-09-26 | Veloxis Pharmaceuticals A/S | Forma de dosificación oral de una vez al día que comprende tacrolimus |
US8821928B2 (en) | 2007-06-04 | 2014-09-02 | Egalet Ltd. | Controlled release pharmaceutical compositions for prolonged effect |
EP2200607A4 (en) | 2007-09-10 | 2012-02-22 | Calcimedica Inc | COMPOUNDS MODULATING INTRACELLULAR CALCIUM |
EP2042165A1 (de) * | 2007-09-28 | 2009-04-01 | Swiss Caps Rechte und Lizenzen AG | Hot-Melt-Befüllte Weichkapseln |
JP5782377B2 (ja) | 2008-08-27 | 2015-09-24 | カルシメディカ,インク. | 細胞内カルシウムを調節する化合物 |
US9005660B2 (en) | 2009-02-06 | 2015-04-14 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
EP2445487A2 (en) | 2009-06-24 | 2012-05-02 | Egalet Ltd. | Controlled release formulations |
US7718662B1 (en) | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
DK2575769T3 (en) | 2010-02-17 | 2016-09-26 | Veloxis Pharmaceuticals As | stabilized tacrolismussammensætning |
JP2013521318A (ja) * | 2010-03-08 | 2013-06-10 | ラティオファルム ゲー・エム・ベー・ハー | ダビガトランエテキシラートを含有する医薬組成物 |
US20130030237A1 (en) | 2010-04-15 | 2013-01-31 | Charles Theuer | Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors |
AU2011248579A1 (en) | 2010-04-27 | 2012-11-29 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
PL2563776T3 (pl) | 2010-04-27 | 2017-01-31 | Calcimedica Inc | Związki, które modulują wewnątrzkomórkowy wapń |
CN103180316A (zh) | 2010-08-27 | 2013-06-26 | 钙医学公司 | 调节细胞内钙的化合物 |
EP2455068A1 (en) * | 2010-11-09 | 2012-05-23 | F. Hoffmann-La Roche AG | Pharmaceutical composition for treating HCV infections |
WO2013037396A1 (en) * | 2011-09-12 | 2013-03-21 | Bioneer A/S | Solution of polymer in api for a solid dosage form |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
EP2649989B1 (en) | 2012-04-13 | 2017-10-18 | King Saud University | Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof |
US8313774B1 (en) | 2012-06-26 | 2012-11-20 | Magnifica Inc. | Oral solid composition |
WO2014059333A1 (en) | 2012-10-12 | 2014-04-17 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
US9611263B2 (en) | 2013-10-08 | 2017-04-04 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
JP6345786B2 (ja) | 2013-12-05 | 2018-06-20 | ファーマサイクリックス エルエルシー | ブルトン型チロシンキナーゼの阻害剤 |
CN106456595A (zh) | 2014-02-10 | 2017-02-22 | 帕塔拉制药有限责任公司 | 用于系统性病症的肥大细胞稳定剂治疗 |
SI3104854T1 (sl) | 2014-02-10 | 2020-09-30 | Respivant Sciences Gmbh | Stabilizatorji mastocitov za zdravljenje pljučnih bolezni |
WO2015164213A1 (en) | 2014-04-23 | 2015-10-29 | The Research Foundation For The State University Of New York | A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith |
JP6235755B2 (ja) * | 2014-07-02 | 2017-11-22 | ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク | 高いカーゴ対サーファクタント比を有するサーファクタント除去ミセル組成物 |
US9839644B2 (en) | 2014-09-09 | 2017-12-12 | ARKAY Therapeutics, LLC | Formulations and methods for treatment of metabolic syndrome |
US9359316B1 (en) | 2014-11-25 | 2016-06-07 | Concentric Analgesics, Inc. | Prodrugs of phenolic TRPV1 agonists |
US10227333B2 (en) | 2015-02-11 | 2019-03-12 | Curtana Pharmaceuticals, Inc. | Inhibition of OLIG2 activity |
WO2016138479A1 (en) | 2015-02-27 | 2016-09-01 | Curtana Pharmaceuticals, Inc. | Inhibition of olig2 activity |
EP3331522A1 (en) | 2015-08-07 | 2018-06-13 | Patara Pharma LLC | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
US10265296B2 (en) | 2015-08-07 | 2019-04-23 | Respivant Sciences Gmbh | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
WO2017147146A1 (en) | 2016-02-23 | 2017-08-31 | Concentric Analgesics, Inc. | Prodrugs of phenolic trpv1 agonists |
US11883381B2 (en) | 2016-05-12 | 2024-01-30 | The Regents Of The University Of Michigan | ASH1L inhibitors and methods of treatment therewith |
US10821105B2 (en) | 2016-05-25 | 2020-11-03 | Concentric Analgesics, Inc. | Prodrugs of phenolic TRPV1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia |
WO2017205766A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
WO2017205769A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
WO2017205762A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
EA201990508A1 (ru) | 2016-08-26 | 2019-09-30 | Куртана Фармасьютикалс, Инк. | ИНГИБИРОВАНИЕ АКТИВНОСТИ Olig2 |
JP2019528320A (ja) | 2016-08-31 | 2019-10-10 | レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングRespivant Sciences Gmbh | 特発性肺線維症による慢性咳の治療のためのクロモリン組成物 |
CN109803724A (zh) | 2016-10-07 | 2019-05-24 | 瑞思皮万特科学有限责任公司 | 用于治疗肺纤维化的色甘酸组合物 |
US11382897B2 (en) | 2017-11-07 | 2022-07-12 | The Regents Of The University Of Michigan | Therapeutic combination for treatment of cerebellar ataxia |
JP2021502388A (ja) | 2017-11-10 | 2021-01-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Ash1l阻害剤及びそれを用いた治療方法 |
EP3720439A4 (en) | 2017-12-07 | 2021-09-08 | The Regents Of The University Of Michigan | NSD FAMILY INHIBITORS AND TREATMENT METHODS INCLUDING THESE |
WO2019169112A1 (en) | 2018-02-28 | 2019-09-06 | Curtana Pharmaceuticals, Inc. | Inhibition of olig2 activity |
JP2021527064A (ja) | 2018-06-07 | 2021-10-11 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Prc1阻害剤及びそれを用いた治療方法 |
TW202019887A (zh) | 2018-07-27 | 2020-06-01 | 美商同心止痛劑股份有限公司 | 酚系trpv1促效劑之聚乙二醇化前藥 |
US20200069742A1 (en) | 2018-08-29 | 2020-03-05 | Myos Rens Technology Inc. | Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals |
US20200108102A1 (en) | 2018-10-03 | 2020-04-09 | Myos Rens Technology Inc. | Spray dried follistatin product |
WO2020096660A1 (en) | 2018-11-06 | 2020-05-14 | Myos Rens Technology, Inc. | Methods and compositions for improving skeletal muscle protein fractional synthetic rate |
WO2020142557A1 (en) | 2018-12-31 | 2020-07-09 | Biomea Fusion, Llc | Irreversible inhibitors of menin-mll interaction |
US11833186B2 (en) | 2019-02-01 | 2023-12-05 | Myos Corp. | Methods and compositions for improving quality of life and increasing activity in aging and chronically ill mammals |
SG11202109899VA (en) | 2019-03-15 | 2021-10-28 | Unicycive Therapeutics Inc | Nicorandil derivatives |
CA3185209A1 (en) | 2020-07-10 | 2021-01-27 | Alyssa WINKLER | Gas41 inhibitors and methods of use thereof |
CA3202151A1 (en) | 2020-12-16 | 2022-06-23 | Biomea Fusion, Inc. | Fused pyrimidine compounds as inhibitors of menin-mll interaction |
TW202320796A (zh) | 2021-08-11 | 2023-06-01 | 美商拜歐米富士恩股份有限公司 | 用於糖尿病的menin-mll相互作用之共價抑制劑 |
WO2023027966A1 (en) | 2021-08-24 | 2023-03-02 | Biomea Fusion, Inc. | Pyrazine compounds as irreversible inhibitors of flt3 |
WO2023039240A1 (en) | 2021-09-13 | 2023-03-16 | Biomea Fusion, Inc. | IRREVERSIBLE INHIBITORS OF KRas |
WO2023086341A1 (en) | 2021-11-09 | 2023-05-19 | Biomea Fusion, Inc. | Inhibitors of kras |
TW202340177A (zh) | 2021-12-30 | 2023-10-16 | 美商拜歐米富士恩股份有限公司 | 作為 flt3抑制劑之吡嗪化合物 |
WO2023235618A1 (en) | 2022-06-03 | 2023-12-07 | Biomea Fusion, Inc. | Fused pyrimidine compounds as inhibitors of menin |
WO2024086613A2 (en) | 2022-10-19 | 2024-04-25 | Myos Corp. | Myogenic compounds |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2698822A (en) * | 1951-04-28 | 1955-01-04 | Fougera & Co Inc E | Cardiac glycoside buccal composition |
US2988484A (en) * | 1956-07-24 | 1961-06-13 | Drew & Co Inc E F | Alcohol soluble pharmaceutical compositions |
US3308217A (en) * | 1965-02-09 | 1967-03-07 | Lowy Lawrence | Method of granulating materials for subsequent forming into tablets |
US3374146A (en) * | 1966-04-18 | 1968-03-19 | American Cyanamid Co | Sustained release encapsulation |
US3857933A (en) * | 1969-10-17 | 1974-12-31 | Hoechst Ag | Process for the manufacture of a drug dosage form permitting controlled release of active ingredient |
US3867521A (en) * | 1970-08-26 | 1975-02-18 | Scherer Corp R P | Method for absorption of drugs |
US4151273A (en) * | 1974-10-31 | 1979-04-24 | The Regents Of The University Of California | Increasing the absorption rate of insoluble drugs |
JPS53107408A (en) * | 1977-02-28 | 1978-09-19 | Yamanouchi Pharmaceut Co Ltd | Micellar preparation for rectal infusion |
GB1598458A (en) * | 1977-04-01 | 1981-09-23 | Hoechst Uk Ltd | Tableting of microcapsules |
GB1572226A (en) * | 1977-11-03 | 1980-07-30 | Hoechst Uk Ltd | Pharmaceutical preparations in solid unit dosage form |
US4344934A (en) * | 1978-11-20 | 1982-08-17 | American Home Products Corporation | Therapeutic compositions with enhanced bioavailability |
JPS5618914A (en) * | 1979-07-25 | 1981-02-23 | Eisai Co Ltd | Ubidecarenone composition having good absorbability |
US4454152A (en) * | 1980-05-07 | 1984-06-12 | Hoffmann-La Roche Inc. | Methoxsalen dosage forms |
JPS5953410A (ja) * | 1982-09-20 | 1984-03-28 | Fujisawa Pharmaceut Co Ltd | 新型ソフトカプセル剤 |
LU84515A1 (fr) * | 1982-12-09 | 1984-10-22 | Oreal | Composition stable pour corticotherapie locale a forte concentration hydrocortisone solubilisee |
US4797288A (en) * | 1984-10-05 | 1989-01-10 | Warner-Lambert Company | Novel drug delivery system |
DE3437599C2 (de) * | 1984-10-13 | 1987-04-16 | Dolorgiet GmbH & Co KG, 5205 St Augustin | Ibuprofen enthaltende Weichgelatinekapseln |
DE3438830A1 (de) * | 1984-10-23 | 1986-04-30 | Rentschler Arzneimittel | Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung |
JPS61221131A (ja) * | 1985-03-28 | 1986-10-01 | Eisai Co Ltd | 吸収促進したユビデカレノン含有組成物 |
GB8524421D0 (en) * | 1985-10-03 | 1985-11-06 | Boots Co Plc | Therapeutic agents |
NZ220599A (en) * | 1986-06-16 | 1990-10-26 | Merck & Co Inc | Controlled release oral dosage formulation of carbidopa and levodopa |
US4708966A (en) * | 1986-06-27 | 1987-11-24 | The Procter & Gamble Company | Novel anti-inflammatory agents, pharmaceutical compositions and methods for reducing inflammation |
US5071643A (en) * | 1986-10-17 | 1991-12-10 | R. P. Scherer Corporation | Solvent system enhancing the solubility of pharmaceuticals for encapsulation |
CH668553A5 (de) * | 1987-02-02 | 1989-01-13 | Mepha Ag | Arzneimittel mit verzoegerter wirkstofffreisetzung. |
US4847071A (en) * | 1987-10-22 | 1989-07-11 | The Procter & Gamble Company | Photoprotection compositions comprising tocopherol sorbate and an anti-inflammatory agent |
US4847303A (en) * | 1987-11-23 | 1989-07-11 | The Procter & Gamble Company | Tert-butylphenyl compounds useful as anti-inflammatory agents |
US4849428A (en) * | 1987-11-23 | 1989-07-18 | The Procter & Gamble Company | Cyclic anti-inflammatory derivatives of di-tert-butylphenol compounds, compositions and use |
US4936074A (en) * | 1988-11-17 | 1990-06-26 | D. M. Graham Laboratories, Inc. | Process for preparing solid encapsulated medicament |
US5073374A (en) * | 1988-11-30 | 1991-12-17 | Schering Corporation | Fast dissolving buccal tablet |
ATE104547T1 (de) * | 1989-11-22 | 1994-05-15 | Procter & Gamble | Pharmazeutische tebufelon-zusammensetzungen. |
-
1992
- 1992-05-19 US US07/885,932 patent/US5281420A/en not_active Expired - Fee Related
-
1993
- 1993-04-30 EP EP93910914A patent/EP0641199A1/en not_active Withdrawn
- 1993-04-30 CA CA002135603A patent/CA2135603C/en not_active Expired - Fee Related
- 1993-04-30 JP JP5520259A patent/JPH10512845A/ja active Pending
- 1993-04-30 WO PCT/US1993/004050 patent/WO1993023022A1/en not_active Application Discontinuation
-
1994
- 1994-11-18 FI FI945437A patent/FI945437A0/fi unknown
Also Published As
Publication number | Publication date |
---|---|
WO1993023022A1 (en) | 1993-11-25 |
EP0641199A1 (en) | 1995-03-08 |
US5281420A (en) | 1994-01-25 |
CA2135603C (en) | 1998-09-22 |
CA2135603A1 (en) | 1993-11-25 |
FI945437A0 (fi) | 1994-11-18 |
JPH10512845A (ja) | 1998-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI945437A0 (fi) | Kiinteitä tebufelonidispersiokoostumuksia | |
DE69325158D1 (de) | Photokromische Zusammensetzung | |
DE69423670D1 (de) | Siloxy-aluminoxan-Zusammensetzungen | |
DE69326743D1 (de) | Tintenzusammensetzungen | |
DE69311550D1 (de) | Sulfopolymer/vanadiumoxid - antistatische zusammensetzungen | |
DE69322711D1 (de) | Farbändernde Zusammensetzungen | |
DE69322946D1 (de) | Photolackzusammensetzung | |
DE69301999D1 (de) | Photoresist Zusammensetzung | |
KR950703926A (ko) | 화장제 조성물(Cosmetic Composition) | |
DE69305255D1 (de) | Beschichtungszusammensetzungen | |
DE69314838D1 (de) | Bindemittelzusammensetzung | |
DE69310957D1 (de) | Organosiliconzusammensetzungen | |
BR9204816A (pt) | Dispersao acrillica anionica pos-diluida | |
NO933467D0 (no) | Ioderte aroyloksykarboksamider | |
DE69123586D1 (de) | Modifizierte Dispergierzusammensetzungen | |
ITMI920347A0 (it) | Composizioni poliolefiniche termosaldabili | |
DE69313922D1 (de) | Polypropylene-Copolyphthalamid Zusammensetzungen | |
BR9406627A (pt) | Composições antiparasiticas | |
BR9307800A (pt) | ComposiçÕes anticárie | |
DE69322346D1 (de) | Fotoresist-Zusammensetzungen | |
BR9302852A (pt) | Conjunto quebrador de crosta | |
DE69320891D1 (de) | Pestizide Zusammensetzung | |
DK0651034T3 (da) | Begroningsbeskyttende malingsammensætning | |
DE69217904D1 (de) | Zusammensetzung | |
DE69123585D1 (de) | Modifizierte Dispergierzusammensetzungen |